First-of-Its-Kind Nationwide Survey from Myovant Sciences and Evidation Health Captures Impact of Menstrual Stigma and Sympto...
October 17 2019 - 5:00AM
Pervasive stigma and prevalent symptoms related to menstruation are
among the key takeaways from a new survey conducted by Myovant
Sciences (NYSE: MYOV), a healthcare company focused on
developing innovative treatments for women's health and prostate
cancer, and Evidation Health, a health and measurement company that
helps life sciences companies understand how everyday behavior and
health interact.
Initial findings include:
- STIGMA IS PERVASIVE AND MENSTRUATION IS INSUFFICIENTLY
DISCUSSED:• Over 60% of female and male respondents believe there
is stigma around menstruation in society today.• About 1 in 5
female respondents do not feel comfortable talking about
menstruation with their healthcare provider, and about 1 in 10 male
respondents do not feel comfortable talking about menstruation with
anyone.
- MENSTRUAL SYMPTOMS ARE COMMON AND HAVE AN IMPACT ON DAILY
ACTIVITIES:• About 1 in 4 female respondents report heavy menstrual
bleeding (23%) or severe menstrual pain (26%) during their last
period.• Female respondents with heavy menstrual bleeding took
fewer steps (5%) and female respondents with severe menstrual pain
spent more nights (48%) with less than 4 hours of continuous sleep
than those without these symptoms.• Over 80% of female respondents
report experiencing heavy menstrual bleeding or menstrual pain at
some point in their lives.
- MENSTRUAL CYCLE TRACKING IS COMMON, ESPECIALLY WITH MOBILE
APPS:• Over 75% of female respondents track their menstrual cycles.
Of these, 78% use mobile apps. Across all age groups, female
respondents use mobile apps as the primary method for tracking.•
The most frequently cited motivations for using mobile apps include
predicting the onset of menstruation, tracking menstrual bleeding,
and learning more about health.
“It is clear stigma around menstruation is widespread and has
real-life consequences,” said Lynn Seely, M.D., President and CEO
of Myovant Sciences. “Heavy menstrual bleeding and severe menstrual
pain are common and impact daily activities, and yet so many are
uncomfortable talking about it. This survey clearly shows the need
for elevating the conversation around periods and provides us with
new, actionable information as we continue to advocate for change
in women’s health.”
Deployed through the Evidation health app, Achievement, which
engages with a population of over 3 million people across the U.S.,
the survey explored the prevalence and impact of common but
understudied menstrual symptoms, focusing on heavy menstrual
bleeding and menstrual pain. These symptoms can indicate underlying
diseases, such as uterine fibroids and endometriosis, that are
often left undiagnosed due to normalization and silencing of
symptoms.
Over 13,000 females and males elected to share their survey
insights in this web-based report. The sample included both female
and male respondents from all 50 states, the District of Columbia,
and Puerto Rico.
“This survey demonstrates how much we can learn through
measuring health in everyday life, especially in areas like women’s
health where so much remains understudied,” said Christine Lemke,
Co-Founder and President of Evidation. “Not only is there a need
for more research, but there is also a clear demand. This survey
was one of the fastest ever to enroll on Achievement and we
received very positive feedback from our users. Innovative
collaborations like this one have the potential to create a new
paradigm for advancing women’s health.”
PERIOD. Inc. collaborated with Myovant and Evidation to develop
the questionnaire to assess education, stigma, and conversations
around menstruation.
“I have spent over five years building an organization to fight
period poverty and period stigma, but this is the first time we
have had detailed, large-scale information on the problem,” said
Nadya Okamoto, Founder and Executive Director of PERIOD. “This
survey demonstrates that stigma is pervasive, with consequences for
people all across the U.S. We are thrilled to work with partners
like Myovant and Evidation to better understand the impact of
menstrual symptoms and stigma. It is through collaborations like
this one that we can advance our shared commitment to menstrual
equity.”
About Myovant SciencesMyovant
Sciences aspires to be the leading healthcare company focused
on innovative treatments for women’s health and prostate cancer.
The company’s lead product candidate is relugolix, a once-daily
oral GnRH receptor antagonist. The company has three
late-stage clinical programs for relugolix in uterine fibroids,
endometriosis, and prostate cancer. The company is also
developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist,
that has completed a Phase 2a study for the treatment of female
infertility as part of assisted reproduction. Takeda
Pharmaceuticals International AG granted the company an
exclusive, worldwide license to develop and commercialize relugolix
(excluding Japan and certain other Asian countries) and
an exclusive license to develop and commercialize MVT-602 in all
countries worldwide. For more information, please visit the
company’s website at www.myovant.com. Follow @Myovant on
Twitter and LinkedIn.
About Evidation HealthEvidation Health is a new
kind of health and measurement company that provides the world’s
most innovative life sciences and health care companies the
technology and expertise they need to understand how everyday
behavior and health interact. The volume of behavior data generated
from smartphones and connected sensors — including wearables and
medical devices — has opened up new ways to analyze individuals’
behavior and health in real time, unlocking insights into what
medicines and treatments work best and spotting significant changes
in health earlier. The scale and utility of everyday behavior data
has the potential to be one of the most transformative forces in
medicine, and Evidation Health is leading the way.
Over the years, Evidation has built the largest, most diverse
virtual pool of research participants through its proprietary and
popular app, Achievement. With a direct and trusted relationship
with more than 3 million individuals, its deep research expertise,
and its data platform, Evidation can undertake real world research
for life sciences and health care companies — and, ultimately,
transform how health is measured and how diseases are identified,
treated, and monitored. Founded in 2012, Evidation Health is
headquartered in San Mateo, Calif., with additional offices in San
Francisco and Santa Barbara, Calif. To learn more, visit
evidation.com, or follow us on Twitter @evidation.
About PERIOD. Inc.PERIOD's mission is to end
period poverty and stigma through service, education, and
advocacy. Through a network of over 600 registered chapters in
all 50 states PERIOD distributes menstrual products to people in
need; educates to change the way people think, talk, and learn
about periods; and advocates for systemic change to ensure
equitable access to menstrual care. PERIOD was founded in 2014
by Nadya Okamoto and Vincent Forand when they were juniors in high
school. Since then, PERIOD has served over 900,000
periods. For more information, please
visit www.period.org.
Myovant Media Contact:Albert LiaoDirector,
Corporate CommunicationsMyovant Sciences, Inc.media@myovant.com
Evidation Media Contact:Simon
Brownevidation@crosscutstrategies.com202-792-7200
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Apr 2023 to Apr 2024